Enzymes Market Size, Share & COVID-19 Impact Analysis, By Type (Industrial Enzymes and Specialty Enzymes), By Source (Plants, Animals, and Microorganisms), By Product Type (Protease, Lipase, Carbohydrates, Nuclease & Polymerase, and Others) and Regional Forecast 2020-2027

The global enzymes market size was valued at USD 9,008.7 million in 2019 and is expected to grow from USD 8,919.8 million in 2020 to USD 13,815.2 million in 2027, exhibiting a CAGR of 6.4% in the 2020-2027 period. North America dominated the global market with a share of 39.78% in 2019.

Based on our analysis, the market exhibited a decline of 1.0% in 2020. The impact of COVID-19 has been staggering, with the market witnessing a negative demand across the globe amid the pandemic. The sudden rise in CAGR after 2020 is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.

Growing consumer awareness regarding improved food quality, and considerable consumption of dietary supplements, are some of the primary factors contributing to the market growth. The growth of the enzymes market is majorly driven by the growing demand for effective polymerases, nucleases, and other pharmaceuticals. Due to this factor, various pharmaceutical companies are focusing on the development of novel enzyme-based pharmaceuticals. 

For instance, Creative Enzymes Company offers high purity products for diagnostic products for the development of diagnostic and analytical tools. In August 2019, the company announced the launch of its products, which can be used for multiple applications. These novel products range from daily use to industrial use and can be utilized in various fields, including diagnostics, research, environment protection, daily use, etc.

Increasing Research and New Product Launch amid COVID-19 to Boost Revenue

COVID-19 impact on the market is estimated to reflect a decline in the year 2020 and across. The demand for enzyme-based pharmaceutical areas is expected to drop drastically in 2020 compared to 2019. Owing to the COVID-19 pandemic, leading players operating in the development of enzymes are currently working on manufacturing sanitizers to fight against COVID-19. For example, in April 2020, BASF, one of the largest manufacturers, started the production of hand sanitizer in New Jersey to support the fight against COVID-19. This may root a substantial decline in the growth of the market globally.

LATEST TRENDS

Growing Technological Advancements Offer Enormous Opportunity for Market Growth

The incorporation of advanced technology in the manufacturing process is the latest trend in the market. The increasing use of enzymes for industrial processes has surged the clinical studies for biocatalysts with novel or improved properties. This is carried out by incorporating some imminent technologies of gene editing and new bacterical platform for therapeutic enzymes. Various companies are focusing on technological advancements for the development of innovative products. For instance, in October 2022, Ginkgo Bioworks collaborated Merck to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. This collaboration is anticipated to fast-track the commercialization and creation of novel, low-cost small molecule enzyme-based pharmaceuticals.

DRIVING FACTORS

Increasing Prevalence Of Chronic Ailments to Drive Market Growth

The growing usage of enzyme-based products in therapies for diseases, such as cardiovascular diseases, cancer, and lysosomal disorders, is anticipated to drive the demand for products during the forecast period. Pharmaceutical producers are gradually becoming aware of the incorporation of biocatalysts into the manufacturing process. The high incidence rate of cancer across the globe is one of the major factors supporting the growth of the market during the analysis period. For instance, as per the American Cancer Society 2023 Statistics, cancer is the second most common cause of death in the U.S., and 1,958,310 new cancer cases are expected to be diagnosed with cancer and 609,820 cancer deaths in the U.S. by the end of 2023. Hence, the surging prevalence of such chronic ailments will strongly support the market growth during the projected timeline.  

RESTRAINING FACTORS

Lack of Standard Regulatory Scenario Coupled High Prices Of Raw Materials and Products May Restrain Market Growth

The dearth of standardized regulatory norms and harmonization will restrict the enzymes market growth. For instance, the European regulatory norms associated with the approval of additives in the feedstuff might cause complexities among the product manufacturers in the region. The high cost associated with enzymes is caused due to expensive equipment and high operating cost. Moreover, the high price of products is among the key factors restraining industry growth.

SEGMENTATION

By Type Analysis

Industrial Segment to Lead the Market Due to their Rising Applications in Chronic Diseases

Based on type, the global market is categorized into industrial and specialty. Among them, the industrial segment is expected to capture significant enzymes market share across the forecast period. High growth of the segment is attributable to the rising number of clinical trials being conducted across the globe to evaluate the potency and efficacy of these products in various disease applications.

The specialty segment is poised to witness significant CAGR during the forecast period. The stable share is attributable to the increasing number of strategic developments such as partnerships among major players to develop novel products. For instance, in July 2021, Codexis, Inc. expanded its research collaboration and signed an exclusive supply agreement with Kalsec, Inc. to develop novel enzymes by using Codexis’ CodeEvolver technology platform.

By Source Analysis

Microorganisms Segment to Hold Largest Market Share

In terms of source, the microorganisms segment dominated the enzymes market in terms of value in 2019. The leading share of the segment is attributable to the growing usage of microorganism-based products in various applications. In addition, the microbial products have been paying more attention due to their active and stable nature compared to products from animals and plants.

The plants segment is anticipated to experience significant growth during 2021-2028. The high growth of the segment is primarily due to the rising number of plant-based products launched in the past few years. For instance, in April 2021, Amano Enzymes launched a plant-based enzyme called Umamizyme Pulse to amplify plant-based applications.

By Product Type Analysis

Carbohydrates Segment to Hold Largest Market Share

In terms of product type, the carbohydrates segment held the leading market share in 2019. The high growth of the segment is backed by the increasing number of clinical trials for evaluating the efficacy of carbohydrate-based products for several health conditions. Moreover, the growing prevalence of metabolic syndromes across the globe is another major factor supporting the usage of such products. For instance, as per a study published by the Diabetes Research and Clinical Practice in June 2022, the global prevalence of metabolic syndrome is between 12.5% and 31.4%.

The protease segment is expected to experience considerable growth in the forthcoming years. The high growth of the segment is attributable to the increasing number of product launches. For instance, in July 2023, Biocatalysts launched Promod128L, a novel protease preparation that offers a wide range of applications in pharmaceuticals, supplements, and biomaterials.

REGIONAL INSIGHTS

The enzymes market in North America accounted for USD 3,584.0 million in 2019. The rising number of clinical trials to develop potent therapeutics, especially in the U.S., is one of the key factors for the high growth of the region. There is a strong presence of enzyme manufacturers in this region, which offers growth potential for enzymes market growth. Moreover, the increasing number of product launches across the U.S. is further expected to support the expansion of the global market in this region. In addition, the increasing number of FDA approvals will further stimulate regional growth. For instance, in August 2021, the U.S. FDA approved Nexviazyme (avalglucosidase alfa-ngpt) of Genzyme Corporation, which is intended to treat patients with late-onset Pompe disease.

Europe is anticipated to be the second-largest by the region during the forecast period. The rising funding in research in major countries such as Germany is one of the most significant factors for the regional expansion. Furthermore, this market’s growth in Europe is primarily boosted by growing diversity in applications and niche product launches. 

The market in Asia Pacific is projected to grow at a significantly higher growth rate. This is majorly due to growing adoption of enzyme-based therapeutics and increasing medical tourism in countries such as Thailand and Singapore. Additionally, the growing number of manufacturers expanding their geographic presence across the untrodden economies of the Asia Pacific region will further boost the growth rate.

Rising healthcare expenditure and growing penetration of market players are boosting the market growth in Latin America and the Middle East & Africa. For instance, in June 2019, Novozymes (Denmark) expanded its presence in East Africa. This allowed the company to meet the consumer needs for this type of products in the region. 

KEY INDUSTRY PLAYERS

Increasing Strategic Partnerships amongst Major Players to Propel the Revenue

The market is consolidated in nature with players such as DuPont, Sanofi, DSM, BASF, etc. account for a key portion of the industry. This is attributable to various factors such as a robust distribution network of the companies across the globe, novel product launches, and a strong focus on upgrading the manufacturing facilities for boosting production. For instance, in May 2023, DSM launched Maxilact Next, a novel addition to its highly-valued range of Maxilact lactase enzymes. This novel solution is more efficient and pure lactase that is commercialized in the global market.

LIST OF KEY COMPANIES PROFILED:

• BASF SE (Ludwigshafen, Germany)


• DuPont (Delaware, U.S)


• DSM (Heerlen, Netherlands)


• Novozyme (Bagsværd, Denmark)


• Roche Holding (Basel, Switzerland)


• Codeix (California, U.S.)


• Sanofi (Paris, France)


• Advanced Enzymes (Maharashtra, India)


• F. Hoffmann-La Roche Ltd (Basel, Switzerland)


• Codexis, Inc.  (California, U.S.)


• Advanced Enzyme Technologies (Maharashtra, India)


• Other Prominent Players

KEY INDUSTRY DEVELOPMENTS:

• December 2023 – Aldevron and Codexis, Inc. signed a global licensing agreement for Codex HiCap RNA Polymerase. The collaboration aims to increase commercial penetration and enable efficient manufacture of mRNA-based therapeutics.


• September 2023 – BASF SE further expanded its partnership with Cargill Incorporated to offer enzyme solutions to animal protein producers in the U.S. 


• February 2022 – Kerry Group plc., acquired c-LEcta, a biotechnology company operating in the fields of enzyme engineering and bioprocess development.


• December 2021 – Codexis, Inc., launched Codex HiTemp Reverse Transcriptase to simplify RNA detection in PCR testing, including COVID-19 testing.


• November 2021 – Novozymes and Novo Nordisk AG collaborated to develop speciality enzymes to support the production process in biopharma processing and regenerative medicines.

REPORT COVERAGE

The global enzymes market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product type, application and end-user. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation